Incyte INCY
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$2.97M (11 inflow days, 9 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 40.2% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 4.63% to 5.22% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| BlackRock | Mutual Fund | 2026/Q4 | +1,096,600 | 9.4% |
| Merrill Lynch, Pierce, Fenner & Smith Incorporated | Private Company | 2026/Q4 | +775,774 | 0.5% |
| Jupiter Fund Management Plc | Mutual Fund | 2026/Q4 | +727,973 | 0.6% |
| Allspring Global Investments, LLC | Mutual Fund | 2026/Q4 | +646,890 | 0.4% |
| Bellevue Asset Management AG | Mutual Fund | 2026/Q4 | +489,936 | 0.2% |
| AssetMark, Inc. | Mutual Fund | 2026/Q4 | +477,256 | 0.3% |
| Deka Investment GmbH | Mutual Fund | 2026/Q4 | +474,610 | 0.3% |
| Northern Trust Global Investments | Mutual Fund | 2026/Q4 | +337,922 | 1.0% |
| Baker Bros. Advisors LP | Hedge Fund | 2026/Q3 | +312,565 | 15.2% |
| Virginia Retirement System | Government Pension Fund | 2026/Q4 | +299,014 | 0.4% |
| Franklin Resources | Mutual Fund | 2026/Q4 | +286,732 | 0.4% |
| Pictet Asset Management Limited | Mutual Fund | 2026/Q4 | +262,372 | 0.5% |
| Squarepoint OPS LLC | Hedge Fund | 2026/Q4 | +256,462 | 0.1% |
| AQR Capital Management | Hedge Fund | 2026/Q4 | +245,749 | 2.7% |
| American Century Investment Management | Mutual Fund | 2026/Q4 | +245,153 | 0.3% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 5 Nov 2026 | Steven Stein | Executive VP, Head of Late-stage Development & Chief Medical Officer | Derivative Exercise and Sale | -240,193 | $119.66 | 1,578 |
| 2 Nov 2026 | Thomas Tray | Principal Financial Officer, VP of Finance & Chief Accounting Officer | Open Market Disposition | -610 | $118.96 | 8,056 |
| 14 Oct 2026 | Pablo Cagnoni | President and Global Head of R&D | Derivative Exercise and Sale | -2,642 | $112.71 | – |
| 30 Sep 2026 | Lee Heeson | Executive VP & Head of Incyte International | Sale to Issuer | -463 | $117.14 | 10,694 |
| 29 Sep 2026 | Edmund Harrigan | Independent Director | Other Acquisition | +206 | $121.35 | 21,583 |
| 29 Sep 2026 | Baker Bros. Advisors LP | Other Acquisition | +644 | – | 31,074,895 | |
| 29 Sep 2026 | Paul Clancy | Independent Director | Other Acquisition | +203 | $121.35 | 24,196 |
| 21 Sep 2026 | David Gardner | Chief Strategy Officer | Sale to Issuer | -920 | $126.93 | 1,437 |
| 14 Sep 2026 | Pablo Cagnoni | President and Global Head of R&D | Derivative Exercise and Sale | -23,218 | $120.50 | – |
| 24 Aug 2026 | Soni Basi | Executive Vice President | Sale to Issuer | -504 | $129.72 | 5,245 |
| 18 Aug 2026 | Pablo Cagnoni | President and Global Head of R&D | Open Market Disposition | -10,801 | $125.56 | – |
| 11 Aug 2026 | Pablo Cagnoni | President and Global Head of R&D | Open Market Disposition | -10,803 | $120.04 | 10,801 |
| 4 Aug 2026 | Pablo Cagnoni | President and Global Head of R&D | Open Market Disposition | -10,640 | $122.69 | 21,604 |
| 4 Aug 2026 | Patrick Mayes | Vice President of Biotherapeutic Research | Derivative Exercise and Sale | -2,207 | $123.99 | 1,904 |
| 2 Aug 2026 | Patrick Mayes | Vice President of Biotherapeutic Research | Derivative Exercise and Sale | -45,767 | $122.19 | 1,904 |
| 30 Jul 2026 | Pablo Cagnoni | President and Global Head of R&D | Open Market Disposition | -15,888 | $119.70 | 32,244 |
| 30 Jul 2026 | Patrick Mayes | Vice President of Biotherapeutic Research | Open Market Disposition | -2,187 | $119.41 | 1,904 |
| 22 Jul 2026 | Michael Morrissey | Executive VP & Head of Global Technical Operations | Other Derivative Acquisition | +6,426 | $116.69 | 6,426 |
| 22 Jul 2026 | Michael Morrissey | Executive VP & Head of Global Technical Operations | Other Derivative Acquisition | +8,999 | – | 8,999 |
| 22 Jul 2026 | Lee Heeson | Executive VP & Head of Incyte International | Other Derivative Acquisition | +13,498 | – | 13,498 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 10,649,327 | 5.2% | 5.6 |
| 15 Oct 2026 | 10,025,354 | 4.9% | 5.3 |
| 30 Sep 2026 | 9,987,084 | 4.9% | 6.1 |
| 15 Sep 2026 | 9,981,369 | 4.9% | 7.3 |
| 31 Aug 2026 | 9,364,687 | 4.6% | 7.7 |
| 14 Aug 2026 | 9,389,500 | 4.6% | 6.7 |
No comments yet — be the first to weigh in on INCY.
Sign in to join the discussion.